Thomas Hennessy

Department of Nuclear Medicine Prince of Wales Hospital Randwick 2031 NSW

[ 1 ] - In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate

Objective(s):Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “No Carrier Added” (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu (“NCA-LuTATE”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on...

نویسندگان همکار

Alireza Aslani 1  

Dale Bailey 1  

David Chan 1  

Eric Henry 1  

Kathy Willowson 1  

Paul Roach 1